Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: A multicenter retrospective study.

Andrei Gafita,Wolfgang P. Fendler,Hui Wang,Shahneen Sandhu,Manuel Weber,Rouzbeh Esfandiari,Johannes Czernin,Hendrik Rathke,Isabel Rauscher,Robert Tauber,Ebrahim Delpassand,Wolfgang A. Weber,Ken Herrmann,Jeremie Calais,Matthias Eiber,Michael S. Hofman

Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: A multicenter retrospective study.

2020

Andrei Gafita
Wolfgang P. Fendler
Hui Wang
Shahneen Sandhu
Manuel Weber
Rouzbeh Esfandiari
Johannes Czernin
Hendrik Rathke
Isabel Rauscher
Robert Tauber
Ebrahim Delpassand
Wolfgang A. Weber
Ken Herrmann
Jeremie Calais
Matthias Eiber
Michael S. Hofman

e17543Background: 177Lu-labelled prostate-specific membrane antigen (LuPSMA) radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) is currently under investigation in phas...

Keywords:

Radiology
in patient
Bone marrow
Retrospective cohort study
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations